POLARIS AI PHARMA CORP. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,760 KRW | -3.93% |
|
+19.16% | +55.94% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2020 | 61.32B 44.77M | Sales 2021 | 60.4B 44.09M | Capitalization | 112B 81.85M |
|---|---|---|---|---|---|
| Net income 2020 | 10.96B 8M | Net income 2021 | 6.88B 5.02M | EV / Sales 2020 | 1.62 x |
| Net cash position 2020 | 48.36B 35.3M | Net cash position 2021 | 50.68B 37M | EV / Sales 2021 | 1.02 x |
| P/E ratio 2020 |
13.5
x | P/E ratio 2021 |
16.3
x | Employees | 160 |
| Yield 2020 |
0.79% | Yield 2021 |
1.04% | Free-Float | 73.23% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.93% | ||
| 1 week | +19.16% | ||
| Current month | +17.72% | ||
| 1 month | +23.11% | ||
| 3 months | +60.36% | ||
| 6 months | +67.86% | ||
| Current year | +55.94% |
1 week
9 350.00
12 300.00
1 month
8 250.0012 300.00
Current year
6 330.0012 300.00
1 year
5 900.0012 300.00
3 years
5 900.0013 650.00
5 years
5 110.0018 400.00
10 years
4 935.0041 950.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jae-Chul Kim
CEO | Chief Executive Officer | 63 | - |
Gyeong-Jae Seo
CTO | Chief Tech/Sci/R&D Officer | 58 | - |
Hwan-Bong Yu
BRD | Director/Board Member | 52 | 15-03-26 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jae-Chul Kim
CEO | Chief Executive Officer | 63 | - |
Gyeong-Jae Seo
CTO | Chief Tech/Sci/R&D Officer | 58 | - |
Hwan-Bong Yu
BRD | Director/Board Member | 52 | 15-03-26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 10,760 | -3.93% | 1,425,529 |
| 24-05-09 | 11,200 | -5.41% | 4,818,016 |
| 24-05-08 | 11,840 | +22.69% | 8,968,200 |
| 24-05-07 | 9,650 | +1.58% | 732,493 |
| 24-05-03 | 9,500 | +5.20% | 2,420,143 |
End-of-day quote Korea S.E., May 09, 2024
More quotes
Polaris AI Pharma Corp, formerly ESTECHPHARMA CO., LTD, is a Korea-based company engaged in the development and manufacture of pharmaceuticals. The Company is engaged in the manufacture and sale of peptic ulcer medicine, diabetes medicine, central nervous system medicine, antispasmodics, antipyretics, and painkillers. It has a research and development institute that develops active pharmaceutical ingredients. The company sells its products in domestic and international markets.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +55.94% | 91.76M | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- A041910 Stock
